Cost-Effectiveness in Health and MedicinePeter J. Neumann, Gillian D. Sanders, Louise B. Russell, Joanna E. Siegel, Theodore G. Ganiats A COMPLETE UPDATE AND REVISION OF THE CLASSIC TEXT "At last, a manual of operations for comparing the cost-effectiveness of a preventive service with a treatment intervention." --American Journal of Preventive Medicine Twenty years after the first edition of COST-EFFECTIVENESS IN HEALTH AND MEDICINE established the practical benchmark for cost-effectiveness analysis, this completely revised edition of the classic text provides an essential resource to a new generation of practitioners, students, researchers, and policymakers. Produced by the Second Panel on Cost-Effectiveness in Health and Medicine--a team of 13 experts from fields including decision science, economics, ethics, psychology, and medicine--this new edition is a comprehensive guide to the use of cost-effectiveness analysis as an evaluative tool at the institutional and policy levels. As health care systems face increasing pressure to derive maximum value from expenditures, the guidelines in this new text represent not just the best information available, but a vital guide to health care decision-making in a challenging new era. Completely revised and enriched with examples and expanded coverage, this second edition of COST-EFFECTIVENESS IN HEALTH AND MEDICINE builds on its predecessor's excellence, offering required reading for both analysts and decision makers. |
Contents
Experiences since the Original Panel | 1 |
2 Theoretical Foundations of CostEffectiveness
Analysis in Health and Medicine | 39 |
3 Recommendations on Perspectives for the Reference Case | 67 |
4 Designing a CostEffectiveness Analysis | 75 |
5 Decision Models in CostEffectiveness Analysis | 105 |
6 Identifying and Quantifying the Consequences of Interventions | 137 |
7 Valuing Health Outcomes | 167 |
8 Estimating Costs and Valuations of NonHealth Benefits
in CostEffectiveness Analysis | 201 |
11 Reflecting Uncertainty in CostEffectiveness Analysis | 289 |
12 Ethical and Distributive Considerations | 319 |
13 Reporting CostEffectiveness Analyses | 343 |
Summary of Recommendations by Chapter | 369 |
Overview of Worked Examples | 383 |
The CostEffectiveness of Treatments
for Individuals with Alcohol Use Disorders A Reference Case Analysis | 385 |
The CostEffectiveness of Home
Palliative Care for Patients at the End of Life | 431 |
| 473 | |
9 Evidence Synthesis for Informing CostEffectiveness Analysis | 237 |
10 Discounting in CostEffectiveness Analysis | 277 |
Other editions - View all
Common terms and phrases
Acamprosate alternative Appendix approach assessment assumptions bias cancer caregivers CEA model Chapter Claxton clinical cohort compared consequences consider consumption context cost-effectiveness analysis cost-effectiveness ratio cost-effectiveness threshold costs and effects Decis decision makers decision model discount rate disease drug economic evaluation estimates ethical evidence synthesis example expected value Health and Medicine health benefits Health Econ health interventions health outcomes health utility health-related quality healthcare sector perspective HRQoL ICER identified Impact Inventory important incremental incremental cost-effectiveness ratio individuals M. C. Weinstein maximization measures meta-analysis methods microsimulation naltrexone Neumann opportunity costs options original Panel palliative care patients payer Pharmacoeconomics population potential preference-based priority QALYs quality-adjusted quantify Reference Case analysis relevant scores screening Sculpher Second Panel sensitivity analysis societal perspective specific standard gamble strategy systematic review tion treatment trial valuation welfare economics